Adaptive neoadjuvant endocrine therapy screens out prime population of ribociclib intensive adjuvant therapy  

作　　者：Zhao Bi Tongyue Ren Yongsheng Wang 

机构地区：[1]Breast Cancer Center,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250017,China

出　　处：《Chinese Journal of Cancer Research》2025年第1期115-117,共3页中国癌症研究(英文版)

基　　金：supported by China Postdoctoral Science Foundation(No.2022M721987);Natural Science Foundation of Shandong Province(No.ZR2024QH058).

摘　　要：The latest data from the NATALEE trial showed the absolute 3-year invasive disease-free survival benefit was 4.9%between the experimental and control groups.That is to say,in the intermediate-risk hormone receptor positive/human epidermal growth factor receptor-2 negative subgroup,there are also some patients with primary resistance to ribociclib.These patients benefit less from ribociclib,and they are unable to gain significant benefit even with the intensive adjuvant therapy of ribociclib.Considering the drug toxicity and health economic benefits,a 3-year course of ribociclib may not be appropriate for all intermediate-risk populations.Therefore,how to screen out the prime population for intensive adjuvant therapy of ribociclib needs to worth explored.In this paper,we discussed that the adaptive neoadjuvant endocrine therapy can screen out the prime population for intensive adjuvant therapy of ribociclib.

关 键 词：Breast cancer Ribociclib hormone receptor positive/human epidermal growth factor receptor-2 negative subgroup neoadjuvant endocrine therapy 

分 类 号：R737.9[医药卫生—肿瘤]